Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome)

Belloni, 2012, Recent advances in the management of cutaneous lymphomas, Semin Oncol, 39, 150, 10.1053/j.seminoncol.2012.01.010

Dummer, 2012, Cutaneous lymphomas: molecular pathways leading to new drugs, J Invest Dermatol, 132, 517, 10.1038/jid.2011.370

Gandhi, 2005, A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine), Blood, 106, 4253, 10.1182/blood-2005-03-1309

Kicska, 2001, Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes, Proc Natl Acad Sci USA, 98, 4593, 10.1073/pnas.071050798

Al-Kali, 2010, Forodesine: review of preclinical and clinical data, Future Oncol, 6, 1211, 10.2217/fon.10.83

Axelrod, 1992, Infections complicating mycosis fungoides and Sézary syndrome, JAMA, 267, 1354, 10.1001/jama.1992.03480100060031

Ogura, 2012, Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies, Cancer Sci, 103, 1290, 10.1111/j.1349-7006.2012.02287.x

Robak, 2009, Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases, Molecules, 14, 1183, 10.3390/molecules14031183

Alonso, 2009, Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM, Blood, 114, 1563, 10.1182/blood-2009-02-207654

Lech-Maranda, 2011, Novel systemic drugs for cutaneous T-cell lymphoma, Recent Pat Anticancer Drug Discov, 6, 70, 10.2174/157489211793980051

Duvic, 2009, Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma, Clin Lymphoma Myeloma, 9, 412, 10.3816/CLM.2009.n.082

Whittaker, 2010, Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma, J Clin Oncol, 28, 4485, 10.1200/JCO.2010.28.9066

Dummer, 2012, A prospective international multicentre phase II trial of intravenous pegylated liposomal doxorubicin (PLD) mono-chemotherapy in patients with advanced Mycosis fungoides stage IIB, IVA and IVB (Final Results from EORTC 21012), J Clin Oncol, 30, 4091, 10.1200/JCO.2011.39.8065

Dalton, 1997, Cutaneous T-cell lymphoma, Int J Dermatol, 36, 801, 10.1046/j.1365-4362.1997.00329.x

Guenova, 2014, Novel therapies for cutaneous T-cell lymphoma: what does the future hold?, Expert Opin Investig Drugs, 23, 457, 10.1517/13543784.2014.876407